The Latin America, Middle East and Africa Head And Neck Cancer Therapeutics Market should witness market growth of 19.5% CAGR during the forecast period (2022-2028).
If a head and neck squamous cell carcinoma is to spread, it nearly always does so locally and/or to the neck lymph nodes. Sometimes, malignant squamous cells can be discovered in the lymph nodes of the upper neck despite the absence of cancer in other areas of the head and neck, probably because the source tumor was too small.
This condition is characterized as metastatic squamous cell carcinoma with an unknown (occult) source. Liquor and nicotine consumption (including passive smoking and smokeless tobacco, sometimes known as "chewing tobacco" or "snuff") are the two most significant risk factors for head and neck malignancies, particularly those of the oral cavity, hypopharynx, and voice box.
People who use both cigarettes and alcohol are more likely to acquire these malignancies than those who use either substance alone. The majority of oral and laryngeal squamous cell carcinomas of the head and neck are caused by cigarette and alcohol use. Infection with cancer-causing human papillomavirus (HPV), particularly HPV type 16, is a risk factor for oropharyngeal malignancies involving the tonsils or the base of the tongue.
Head and neck cancer (HNC) are largely a disease inthe developing world. Overall, 67% of HNC and 82% of HNC-related mortality occur in developing nations. Despite this significant cancer burden, emerging nations only represent 5% of worldwide cancer expenditures. Between 2010 and 2030, the incidence and death rates of cancer in Africa are projected to nearly double. Two-thirds of patientscome with advanced malignancies, while 50% of laryngectomee patients in Cape Town require emergency tracheostomy. In impoverished nations, inquiry and therapy are difficult to get.
The Brazil market dominated the LAMEA Head & Neck Cancer Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $50.3 Million by 2028. The Argentina market is experiencing a CAGR of 20.1% during (2022-2028). Additionally, The UAE market would display a CAGR of 19.2% during (2022-2028).
Based on Therapy Type, the market is segmented into Immunotherapy, Chemotherapy, and Targeted Therapy. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Bristol Myers Squibb Company, and Clinigen Group PLC.
If a head and neck squamous cell carcinoma is to spread, it nearly always does so locally and/or to the neck lymph nodes. Sometimes, malignant squamous cells can be discovered in the lymph nodes of the upper neck despite the absence of cancer in other areas of the head and neck, probably because the source tumor was too small.
This condition is characterized as metastatic squamous cell carcinoma with an unknown (occult) source. Liquor and nicotine consumption (including passive smoking and smokeless tobacco, sometimes known as "chewing tobacco" or "snuff") are the two most significant risk factors for head and neck malignancies, particularly those of the oral cavity, hypopharynx, and voice box.
People who use both cigarettes and alcohol are more likely to acquire these malignancies than those who use either substance alone. The majority of oral and laryngeal squamous cell carcinomas of the head and neck are caused by cigarette and alcohol use. Infection with cancer-causing human papillomavirus (HPV), particularly HPV type 16, is a risk factor for oropharyngeal malignancies involving the tonsils or the base of the tongue.
Head and neck cancer (HNC) are largely a disease inthe developing world. Overall, 67% of HNC and 82% of HNC-related mortality occur in developing nations. Despite this significant cancer burden, emerging nations only represent 5% of worldwide cancer expenditures. Between 2010 and 2030, the incidence and death rates of cancer in Africa are projected to nearly double. Two-thirds of patientscome with advanced malignancies, while 50% of laryngectomee patients in Cape Town require emergency tracheostomy. In impoverished nations, inquiry and therapy are difficult to get.
The Brazil market dominated the LAMEA Head & Neck Cancer Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $50.3 Million by 2028. The Argentina market is experiencing a CAGR of 20.1% during (2022-2028). Additionally, The UAE market would display a CAGR of 19.2% during (2022-2028).
Based on Therapy Type, the market is segmented into Immunotherapy, Chemotherapy, and Targeted Therapy. Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Distribution Channel, the market is segmented into Retail & Specialty Pharmacies, Hospital Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Eli Lilly and Company, Merck & Co., Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd., F. Hoffmann-La Roche Ltd., AstraZeneca Plc, Bristol Myers Squibb Company, and Clinigen Group PLC.
Scope of the Study
By Therapy Type
- Immunotherapy
- Chemotherapy
- Targeted Therapy
By Route of Administration
- Injectable
- Oral
By Distribution Channel
- Retail & Specialty Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Eli Lilly and Company
- Merck & Co., Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca Plc
- Bristol Myers Squibb Company
- Clinigen Group PLC
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. LAMEA Head & Neck Cancer Therapeutics Market by Therapy Type
Chapter 5. LAMEA Head & Neck Cancer Therapeutics Market by Route of Administration
Chapter 6. LAMEA Head & Neck Cancer Therapeutics Market by Distribution Channel
Chapter 7. LAMEA Head & Neck Cancer Therapeutics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Eli Lilly and Company
- Merck & Co., Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceuticals Industries Ltd.
- F. Hoffmann-La Roche Ltd.
- AstraZeneca Plc
- Bristol Myers Squibb Company
- Clinigen Group PLC
Methodology
LOADING...
